OVID RSI Chart
Last 7 days
5%
Last 30 days
1.3%
Last 90 days
-18.0%
Trailing 12 Months
-9.0%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 0 | 0 | 0 | 0 |
2023 | 850.6K | 198.5K | 296.4K | 0 |
2022 | 167.0M | 84.3M | 42.9M | 1.5M |
2021 | 61.6M | 110.5M | 159.4M | 208.4M |
2020 | 0 | 0 | 0 | 12.6M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Mar 18, 2024 | levin jeremy m | bought | 50,364 | 2.76 | 18,248 | ceo |
Feb 22, 2024 | rona jeffrey a | acquired | - | - | 28,125 | cbfo |
Feb 22, 2024 | perone thomas michael | acquired | - | - | 28,125 | general counsel, secretary |
Feb 22, 2024 | tardio jason | acquired | - | - | 28,125 | chief operating officer |
Dec 04, 2023 | levin jeremy m | gifted | - | - | -1,146,550 | ceo |
Sep 12, 2022 | tardio jason | sold | -37,289 | 2.15 | -17,344 | chief operating officer |
Jul 01, 2022 | takeda pharmaceutical co ltd | sold | - | - | -5,750,000 | - |
Jul 01, 2022 | takeda pharmaceutical co ltd | acquired | - | - | 5,750,000 | - |
Jul 14, 2021 | rakhit amit | sold | -126,203 | 3.71 | -34,017 | president and cmo |
Jul 14, 2021 | rakhit amit | acquired | 64,292 | 1.89 | 34,017 | president and cmo |
Which funds bought or sold OVID recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 17, 2024 | Artal Group S.A. | unchanged | - | -425,000 | 7,625,000 | 0.19% |
May 16, 2024 | JANE STREET GROUP, LLC | added | 5.26 | -482 | 163,419 | -% |
May 16, 2024 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -38.92 | -13,319 | 18,285 | -% |
May 15, 2024 | D. E. Shaw & Co., Inc. | reduced | -8.95 | -34,665 | 217,355 | -% |
May 15, 2024 | BANK OF NOVA SCOTIA | unchanged | - | -7,500 | 134,664 | -% |
May 15, 2024 | DEUTSCHE BANK AG\ | added | 4.79 | -544 | 73,142 | -% |
May 15, 2024 | STATE STREET CORP | added | 3.15 | -82,794 | 3,524,720 | -% |
May 15, 2024 | WELLINGTON MANAGEMENT GROUP LLP | new | - | 679,824 | 679,824 | -% |
May 15, 2024 | MORGAN STANLEY | reduced | -25.37 | -126,431 | 304,856 | -% |
May 15, 2024 | JACOBS LEVY EQUITY MANAGEMENT, INC | unchanged | - | -10,598 | 190,140 | -% |
Unveiling Ovid therapeutics Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Ovid therapeutics Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
Ovid therapeutics Inc News
Income Statement (Quarterly) | |||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 |
Revenue | - | - | - | 108,972 | 75,000 | 66,160 | 46,280 | 11,102 | 8,327 | 5,551 | 2,776 | - | - | - | 208,382,779 | 107,648,407 | 6,914,034 |
Operating Expenses | -4.2% | 17,565,000 | 18,329,908 | 12,137,804 | 14,246,982 | 14,958,465 | 12,219,192 | 12,814,958 | 14,304,287 | 17,712,472 | - | 26,353,665 | 11,681,734 | 14,312,826 | 31,825,463 | 27,294,429 | 23,317,696 |
S&GA Expenses | -100.0% | - | 7,688,024 | 6,805,213 | 8,248,216 | 8,343,748 | 6,662,985 | 7,631,705 | 8,257,617 | 9,880,203 | - | 8,264,051 | 6,764,341 | 6,629,158 | 15,576,554 | 10,410,643 | 7,442,401 |
R&D Expenses | -2.3% | 10,397,000 | 10,641,884 | 5,332,591 | 5,998,766 | 6,614,717 | 5,556,207 | 5,183,253 | 6,046,670 | 7,832,269 | - | 18,089,614 | 4,917,393 | 7,683,668 | 16,248,909 | 16,883,786 | 15,875,295 |
EBITDA Margin | 3.2% | -169 | -174 | -161 | -244 | -59.79 | -35.69 | -1.60 | -0.81 | -0.54 | 0.74 | 0.60 | 0.81 | 1.12 | - | - | - |
Income Taxes | - | - | - | - | - | - | -25,000 | - | - | 50,000 | - | -349,714 | -294,829 | 1,473,084 | 500,277 | - | - |
Earnings Before Taxes | 23.7% | -11,694,000 | -15,322,034 | -11,252,386 | -12,408,330 | -13,356,209 | -11,529,788 | -11,967,771 | -14,588,414 | -16,058,056 | - | -26,349,762 | -11,679,077 | -14,315,343 | 176,507,584 | -22,029,501 | -16,424,789 |
EBT Margin | 3.2% | -170 | -176 | -163 | -248 | -60.47 | -36.03 | -1.61 | -0.82 | -0.54 | 0.74 | 0.60 | 0.81 | 1.12 | - | - | - |
Net Income | 23.6% | -11,700,000 | -15,322,034 | -11,252,386 | -12,408,330 | -13,356,209 | -11,504,788 | -11,967,771 | -14,588,414 | -16,108,056 | - | -26,000,048 | -11,384,248 | -15,788,427 | 176,007,307 | -22,029,501 | -16,424,789 |
Net Income Margin | 3.2% | -170 | -176 | -163 | -247 | -60.44 | -36.05 | -1.60 | -0.81 | -0.55 | 0.74 | 0.59 | 0.80 | 1.10 | - | - | - |
Free Cashflow | -40.2% | -16,705,000 | -11,913,706 | -10,105,245 | -11,707,797 | -12,113,560 | -9,295,671 | -12,694,973 | -14,328,508 | -20,132,354 | -12,160,462 | -12,160,462 | -10,894,066 | -19,405,376 | - | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -8.6% | 132 | 144 | 125 | 136 | 143 | 155 | 165 | 177 | 191 | 195 | 207 | 218 | 237 | 76.00 | 92.00 | 45.00 | 62.00 | 81.00 | 41.00 | 55.00 | 67.00 |
Current Assets | -15.0% | 93.00 | 110 | 92.00 | 102 | 120 | 131 | 140 | 156 | 170 | 190 | 205 | 216 | 237 | 75.00 | 90.00 | 44.00 | 61.00 | 80.00 | 39.00 | 54.00 | 63.00 |
Cash Equivalents | 20.9% | 33.00 | 27.00 | 57.00 | 72.00 | 63.00 | 45.00 | 60.00 | 75.00 | 169 | 190 | 202 | 212 | 233 | 72.00 | 87.00 | 41.00 | 27.00 | 42.00 | 38.00 | 47.00 | 55.00 |
Net PPE | -10.8% | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Liabilities | -5.2% | 53.00 | 56.00 | 24.00 | 26.00 | 22.00 | 23.00 | 23.00 | 25.00 | 26.00 | 15.00 | 10.00 | 11.00 | 16.00 | 32.00 | 28.00 | 15.00 | 10.00 | 11.00 | 11.00 | 9.00 | 9.00 |
Current Liabilities | -22.4% | 9.00 | 11.00 | 9.00 | 10.00 | 7.00 | 7.00 | - | - | - | 15.00 | 10.00 | 11.00 | 16.00 | 22.00 | 18.00 | 15.00 | 10.00 | 11.00 | 10.00 | 9.00 | 8.00 |
Shareholder's Equity | -10.8% | 78.00 | 88.00 | 101 | 111 | 121 | 132 | 142 | 152 | 165 | 180 | 197 | 207 | 221 | 44.00 | 64.00 | 30.00 | 51.00 | 70.00 | 30.00 | 45.00 | 57.00 |
Retained Earnings | -4.2% | -289 | -277 | -262 | -251 | -238 | -225 | -214 | -202 | -187 | -171 | -145 | -133 | -118 | -294 | -272 | -255 | -233 | -213 | -196 | -179 | -166 |
Additional Paid-In Capital | 0.6% | 368 | 366 | 364 | 362 | 360 | 358 | 356 | 354 | 352 | 351 | 342 | 341 | 339 | 338 | 336 | 286 | 285 | 283 | 226 | 225 | 224 |
Shares Outstanding | 0.1% | 71.00 | 71.00 | 71.00 | 71.00 | 70.00 | 70.00 | 70.00 | 70.00 | 70.00 | 70.00 | 67.00 | 67.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 191 | - | - | - | 125 | - | - | - | 217 | - | - | - | 294 | - | - | - | 26.00 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -40.2% | -16,686 | -11,900 | -10,100 | -11,700 | -12,100 | -9,175 | -12,676 | -13,288 | -20,086 | -11,998 | -10,872 | -19,416 | 160,899 | -14,509 | -1,469 | -17,193 | -18,411 | -16,888 | -9,494 | -11,841 | -12,866 |
Share Based Compensation | 10.0% | 1,968 | 1,789 | 1,631 | 1,949 | 1,917 | 1,730 | 1,782 | 1,720 | 1,325 | 1,315 | 1,162 | 1,257 | 1,320 | 2,051 | 2,616 | 1,555 | 1,303 | 1,127 | 1,184 | 1,252 | 1,643 |
Cashflow From Investing | 141.6% | 20,188 | -48,516 | -4,359 | 20,066 | 30,229 | -4,169 | -1,960 | -80,677 | -1,076 | -161 | -64.03 | -1,583 | -11.51 | -90.48 | -38.30 | 30,941 | 3,836 | -35,008 | -18.58 | 4,995 | -8.97 |
Cashflow From Financing | -99.2% | 228 | 30,033 | 224 | 211 | 67.00 | -43.60 | 82.00 | 110 | 33.00 | 109 | 549 | 116 | 130 | -232 | 47,120 | 169 | 16.00 | 55,886 | 59.00 | -391 | 30,986 |
Condensed Consolidated Statements of Operations (unaudited) - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Revenue: | ||
Total revenue | $ 148 | $ 66 |
Operating expenses: | ||
Research and development | 10,397 | 6,615 |
General and administrative | 7,168 | 8,344 |
Total operating expenses | 17,565 | 14,958 |
Loss from operations | (17,417) | (14,892) |
Other income (expense), net | 5,723 | 1,536 |
Loss before provision for income taxes | (11,694) | (13,356) |
Provision for income taxes | 0 | 0 |
Net loss | $ (11,694) | $ (13,356) |
Net loss per share, basic (in dollars per share) | $ (0.17) | $ (0.19) |
Net loss per share, diluted (in dollars per share) | $ (0.17) | $ (0.19) |
Weighted-average common shares outstanding, basic (in shares) | 70,716,929 | 70,490,704 |
Weighted-average common shares outstanding, diluted (in shares) | 70,716,929 | 70,490,704 |
Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 30,772 | $ 27,042 |
Marketable securities | 59,487 | 78,792 |
Prepaid expenses and other current assets | 2,911 | 3,764 |
Total current assets | 93,170 | 109,598 |
Long-term equity investments | 22,022 | 17,626 |
Restricted cash | 1,931 | 1,931 |
Right-of-use asset, net | 13,628 | 13,894 |
Property and equipment, net | 686 | 769 |
Other noncurrent assets | 174 | 210 |
Total assets | 131,613 | 144,027 |
Current liabilities: | ||
Accounts payable | 3,596 | 3,703 |
Accrued expenses | 4,039 | 6,525 |
Current portion, lease liability | 1,268 | 1,246 |
Total current liabilities | 8,903 | 11,474 |
Long-term liabilities: | ||
Lease liability | 14,430 | 14,756 |
Royalty monetization liability | 30,000 | 30,000 |
Total liabilities | 53,333 | 56,230 |
Stockholders' equity: | ||
Preferred stock, $0.001 par value; 10,000,000 shares authorized; Series A convertible preferred stock, 10,000 shares designated, 1,250 shares issued and outstanding at March 31, 2024 and December 31, 2023 | 0 | 0 |
Common stock, $0.001 par value; 125,000,000 shares authorized; 70,783,961 and 70,691,992 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 71 | 71 |
Additional paid-in-capital | 367,787 | 365,591 |
Accumulated other comprehensive (loss) income | (19) | 1 |
Accumulated deficit | (289,560) | (277,866) |
Total stockholders' equity | 78,279 | 87,797 |
Total liabilities and stockholders' equity | $ 131,613 | $ 144,027 |